May 28 (Reuters) - Drug developer iTeos Therapeutics ITOS.O said on Wednesday it plans to wind down its operations and explore selling its assets, including experimental cancer treatments and an obesity program.
Earlier this month, Britain's GSK GSK.L and iTeos Therapeutics said they have stopped developing an experimental lung cancer drug, belrestotug, after it failed to stop the disease from progressing in two studies.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Shreya Biswas)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。